Taysha Gene Therapies, Inc. (TSHA)
- Previous Close
2.6700 - Open
2.6700 - Bid 2.6100 x 1700
- Ask 2.6700 x 1300
- Day's Range
2.5700 - 2.7400 - 52 Week Range
1.0500 - 4.3200 - Volume
4,210,857 - Avg. Volume
3,582,580 - Market Cap (intraday)
693.055M - Beta (5Y Monthly) 1.02
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3400 - Earnings Date Aug 11, 2025 - Aug 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.35
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
www.tayshagtx.comRecent News: TSHA
View More
Performance Overview: TSHA
Trailing total returns as of 6/12/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TSHA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TSHA
View MoreValuation Measures
Market Cap
698.29M
Enterprise Value
643.05M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
95.97
Price/Book (mrq)
12.68
Enterprise Value/Revenue
89.02
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-35.91%
Return on Equity (ttm)
-159.34%
Revenue (ttm)
7.22M
Net Income Avi to Common (ttm)
-86.77M
Diluted EPS (ttm)
-0.3400
Balance Sheet and Cash Flow
Total Cash (mrq)
116.59M
Total Debt/Equity (mrq)
111.93%
Levered Free Cash Flow (ttm)
-52.28M
Research Analysis: TSHA
View MoreResearch Reports: TSHA
View MoreDaily – Vickers Top Buyers & Sellers for 07/02/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 08/17/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 02/07/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 02/04/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.